Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afimoxifene + plus
- Development stage
- Unknown
- Lead developer
- Besins Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Afimoxifene + plus appears to be a misidentification of **AFIME-200 PLUS**, a pharmaceutical product distributed by **Pharma Drugs & Chemicals**. AFIME-200 PLUS is a fixed-dose combination antibiotic containing **cefixime** (a third-generation cephalosporin) and **ofloxacin** (a fluoroquinolone). Cefixime acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), while ofloxacin inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV. This combination is widely used in India for the treatment of various bacterial infections, including typhoid fever, urinary tract infections, and respiratory tract infections. It should be noted that 'afimoxifene' is a distinct chemical entity (4-hydroxytamoxifen, a selective estrogen receptor modulator) and is not an ingredient in this antibiotic product.
- Brand names
- AFIME-200 PLUSAFIME200 PLUSAFIME 200 PLUS
- Other names
- afime-200-plusafime200-plusafime 200-plusafimoxifene + plus
02
Targets
ESRRG (Estrogen-related receptor gamma)GPER1 (G protein-coupled estrogen receptor 1)ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on afimoxifene + plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afimoxifene + plus.